Screener
AbbVie ABBV International — Collaboration revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer.
The source filing: AbbVie’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 12:28 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001551152-26-000017
Outside the United States, AbbVie’s share of profits was $224 million for the three months ended March 31, 2026 and $209 million for the three months ended March 31, 2025. Other costs for the three months ended March 31, 2026 and 2025 were insignificant.
ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is AbbVie's international — collaboration revenues?
- AbbVie (ABBV) reported international — collaboration revenues of $224M in Q1 2026.
- How has AbbVie's international — collaboration revenues changed year-over-year?
- AbbVie's international — collaboration revenues increased by 7.2% year-over-year, from $209M to $224M.
- What does international — collaboration revenues mean?
- This metric represents the company's proportional share of profits derived from international collaborative arrangements or joint ventures with external pharmaceutical partners. It reflects the economic benefits generated from shared research, development, or commercialization efforts outside of the domestic market. These revenues are typically recognized when the company acts as a participant in a strategic alliance rather than the primary manufacturer or distributor.
Ask your AI about AbbVie's international — collaboration revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude